- Home
- IGR vs SYRE Comparison
IGR vs SYRE Comparison
Compare IGR & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGR
- SYRE
- Stock Information
- Founded
- IGR 2004
- SYRE 2013
- Country
- IGR United States
- SYRE United States
- Employees
- IGR N/A
- SYRE N/A
- Industry
- IGR Finance Companies
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- IGR Finance
- SYRE Health Care
- Exchange
- IGR Nasdaq
- SYRE Nasdaq
- Market Cap
- IGR 752.8M
- SYRE 1.1B
- IPO Year
- IGR N/A
- SYRE 2016
- Fundamental
- Price
- IGR $4.92
- SYRE $17.29
- Analyst Decision
- IGR
- SYRE Buy
- Analyst Count
- IGR 0
- SYRE 5
- Target Price
- IGR N/A
- SYRE $55.00
- AVG Volume (30 Days)
- IGR 747.7K
- SYRE 527.1K
- Earning Date
- IGR 01-01-0001
- SYRE 08-06-2025
- Dividend Yield
- IGR 13.93%
- SYRE N/A
- EPS Growth
- IGR N/A
- SYRE N/A
- EPS
- IGR N/A
- SYRE N/A
- Revenue
- IGR N/A
- SYRE N/A
- Revenue This Year
- IGR N/A
- SYRE N/A
- Revenue Next Year
- IGR N/A
- SYRE N/A
- P/E Ratio
- IGR N/A
- SYRE N/A
- Revenue Growth
- IGR N/A
- SYRE N/A
- 52 Week Low
- IGR $3.88
- SYRE $10.91
- 52 Week High
- IGR $5.70
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- IGR 35.64
- SYRE 56.32
- Support Level
- IGR $4.90
- SYRE $16.43
- Resistance Level
- IGR $5.07
- SYRE $18.00
- Average True Range (ATR)
- IGR 0.08
- SYRE 0.98
- MACD
- IGR -0.03
- SYRE 0.08
- Stochastic Oscillator
- IGR 11.84
- SYRE 68.82
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.